BioSpace News Archive

As the U.S. continues to grapple with solutions to the national opioid addiction epidemic, Brentwood-based Corizon Health is preparing to offer a successful treatment pilot to additional communities the company serves across the U.S.

Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced the Company has entered into a long-term lease agreement to develop a 145,000 square-foot advanced cell manufacturing and research facility in Florham Park, New Jersey.

The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (flibanserin), that requires the company to revise important safety information that women and their health care professionals need to have when considering use of the drug.

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Healthcare Services Group, Inc. of the May 21, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The panel is in late stage development and being prepared for CE-IVD commercialization in the second half of 2019 for use on the QIAstat-Dx multiplex syndromic testing system.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion of the content menu for the NeuMoDx™ 96 and 288 Molecular Systems, as well as the commercial availability of the NeuMoDx 96 mid-throughput version of this family of fully integrated PCR-based systems after the initial launch of the NeuMoDx 288 high-throughput version in early 2019.

Acquisition accelerates US Med-Equip’s expansion, increases number of medical devices to support top hospitals across the nation

True Ventures leads funding, pursues mission to invest in companies of broad and lasting impact

Foundation for Chiropractic Progress Executive Vice President Sherry McAllister, DC, has been named to PR News’ inaugural list of the Top Women in Healthcare for 2019.

Evofem Biosciences, Inc. (NASDAQ: EVFM) (“Evofem”), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc.